<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Tp53 gene expression level showed a significant elevation in the liver fibrosis control (group 2). Tp53 mRNA level reached to about 16-folds of the control level. This CCl
 <sub xmlns="http://www.w3.org/1999/xhtml">4</sub>-induced overexpression of Tp53 was markedly suppressed in MPOE-treated rats to about 2-fold as compared to that in the control (
 <xref ref-type="fig" rid="fig8" class="xref">Figure 8(a)</xref>). At the protein level, p53 immunoreactivity was significantly increased in the liver fibrosis control. Group 3 treated with CCl
 <sub xmlns="http://www.w3.org/1999/xhtml">4</sub> + MPOE showed significantly decreased p53 immunoreactivity (
 <xref ref-type="fig" rid="fig9" class="xref">Figure 9(c)</xref>). 
 <xref ref-type="fig" rid="fig9" class="xref"> Figure 9(e)</xref> summarizes the IHC analysis of p53 protein expression in the different groups. Nonsignificant differences in p53 mRNA and protein levels were detected between groups 1 and 4 (Figures 
 <xref ref-type="fig" rid="fig8" class="xref">8(a)</xref> and 
 <xref ref-type="fig" rid="fig9" class="xref">9</xref>), respectively.
</p>
